Treace Announces Participation in Two Upcoming Investor Conferences
Treace Medical Concepts (Nasdaq: TMCI) will participate in two investor conferences on November 10–11, 2025. The company will appear at the UBS Global Healthcare Conference on Monday, November 10, 2025, with a fireside chat at 11:45 AM ET, and at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025.
A live webcast and replay of the UBS fireside chat will be available on the company’s Investor Relations website at https://investors.treace.com/. Treace routinely posts investor‑important information in the Investor Relations section at www.treace.com and encourages investors to check the site regularly.
Treace Medical Concepts (Nasdaq: TMCI) parteciperà a due conferenze per investitori il 10-11 novembre 2025. L'azienda parteciperà alla UBS Global Healthcare Conference lunedì 10 novembre 2025, con un fireside chat alle 11:45 AM ET, e alla Stifel 2025 Healthcare Conference martedì 11 novembre 2025.
Una trasmissione web in diretta e una replica della fireside chat di UBS saranno disponibili sul sito Investor Relations dell'azienda all'indirizzo https://investors.treace.com/. Treace pubblica regolarmente informazioni importanti per gli investitori nella sezione Investor Relations su www.treace.com e invita gli investitori a controllare il sito regolarmente.
Treace Medical Concepts (Nasdaq: TMCI) participará en dos conferencias para inversores los días 10 y 11 de noviembre de 2025. La empresa aparecerá en la UBS Global Healthcare Conference el lunes 10 de noviembre de 2025, con una charla junto a la chimenea a las 11:45 AM ET, y en la Stifel 2025 Healthcare Conference el martes 11 de noviembre de 2025.
Una transmisión en vivo y la repetición de la charla junto a la chimenea de UBS estarán disponibles en el sitio web de Investor Relations de la empresa en https://investors.treace.com/. Treace publica regularmente información importante para inversores en la sección de Investor Relations en www.treace.com y anima a los inversores a consultar el sitio con regularidad.
Treace Medical Concepts (Nasdaq: TMCI)는 2025년 11월 10일~11일 이틀간 두 개의 투자자 컨퍼런스에 참여합니다. 회사는 2025년 11월 10일 월요일에 UBS Global Healthcare Conference에 참석하여 11:45 AM ET에 fireside chat을 진행하고, 2025년 11월 11일 화요일에는 Stifel 2025 Healthcare Conference에 참석합니다.
UBS fireside chat의 라이브 웹캐스트 및 재방송은 회사의 Investor Relations 웹사이트 https://investors.treace.com/에서 이용할 수 있습니다. Treace는 정기적으로 투자자에게 중요한 정보를 www.treace.com의 Investor Relations 섹션에 게시하며, 투자자들에게 정기적으로 사이트를 확인할 것을 권장합니다.
Treace Medical Concepts (Nasdaq: TMCI) participera à deux conférences pour investisseurs les 10 et 11 novembre 2025. L'entreprise interviendra lors de la UBS Global Healthcare Conference le lundi 10 novembre 2025, avec une séance en tête-à-tête à 11:45 AM ET, et lors de la Stifel 2025 Healthcare Conference le mardi 11 novembre 2025.
Une webdiffusion en direct et la rediffusion de la séance en tête-à-tête UBS seront disponibles sur le site Investor Relations de l'entreprise à l'adresse https://investors.treace.com/. Treace publie régulièrement des informations importantes pour les investisseurs dans la section Investor Relations sur www.treace.com et invite les investisseurs à consulter le site régulièrement.
Treace Medical Concepts (Nasdaq: TMCI) wird an zwei Investorenkonferenzen am 10. und 11. November 2025 teilnehmen. Das Unternehmen wird am UBS Global Healthcare Conference am Montag, dem 10. November 2025, mit einem Fireside-Chat um 11:45 AM ET auftreten, und am Stifel 2025 Healthcare Conference am Dienstag, dem 11. November 2025.
Ein Live-Webcast und eine Wiederholung des UBS-Fireside-Chats werden auf der Website des Unternehmens unter Investor Relations https://investors.treace.com/ verfügbar sein. Treace veröffentlicht routinemäßig für Investoren relevante Informationen im Bereich Investor Relations unter www.treace.com und ermutigt Investoren, die Seite regelmäßig zu prüfen.
Treace Medical Concepts (Nasdaq: TMCI) ستشارك في مؤتمرات المستثمرين في يومي 10 و11 نوفمبر 2025. ستظهر الشركة في UBS Global Healthcare Conference يوم الاثنين 10 نوفمبر 2025، مع جلسة fireside عند11:45 AM ET، وفي Stifel 2025 Healthcare Conference يوم الثلاثاء 11 نوفمبر 2025.
سيكون البث المباشر وإعادة بث جلسة fireside الخاصة بـ UBS متاحين على موقع الشركة Investor Relations على https://investors.treace.com/. Treace تنشر بانتظام معلومات مهمة للمستثمرين في قسم Investor Relations على www.treace.com وتحث المستثمرين على التحقق من الموقع بانتظام.
- None.
- None.
PONTE VEDRA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will participate in the following upcoming investor conferences.
- The UBS Global Healthcare Conference on Monday, November 10, 2025, with a fireside chat at 11:45 am ET; and
- The Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025
A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion surgeons and address the four classes of bunions, Treace introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. Treace continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate® Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty®, Adductoplasty® and SpeedMTP™ procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net